Advertisement

Laboratory Methods for Assessing and Licensing Influenza Vaccines for Poultry

  • David E. SwayneEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 2123)

Abstract

Avian influenza (AI) vaccines for poultry are based on hemagglutinin (HA) proteins, and protection is specific to the subtype. An estimated 313 billion doses have been used between 2002 and 2018 for high pathogenicity AI control. No universal vaccines are currently available. The majority of AI vaccines are inactivated whole influenza viruses that are grown in embryonating chicken eggs, emulsified in oil adjuvant systems, and injected subcutaneously or intramuscularly. Live virus-vectored vaccines such as recombinant viruses of fowl pox, Newcastle disease, and herpesvirus of turkeys containing inserts of AI virus HA genes have been used on a more limited basis. Also, vaccines have been licensed or registered based on baculovirus and defective replicating alphavirus (RNA particles) expressing HA protein or DNA vaccine with HA gene insert. In studies to evaluate vaccine efficacy and potency, the protocol design and its implementation should address the biosafety level needed for the work, provide information required for approval by Institutional Biosafety and Animal Care Committees, contain information on seed strain selection, provide needed information on animal subjects and their relevant parameters, and address the selection and use of challenge viruses. Various metrics have been used to directly measure vaccine-induced protection, including prevention of death, clinical signs, and lesions; prevention of decreases in egg production and alterations in egg quality; quantification of the reduction in virus replication and shedding from the respiratory tract and gastrointestinal tracts; and prevention of contact transmission in in vivo poultry experiments. In addition, indirect measures of vaccine potency and protection have been developed and validated against the direct measures and include serological assays in vaccinated poultry and the assessment of the content of HA antigen in the vaccine. These indirect assessments of protection are useful in determining if vaccine batches have a consistent ability to protect. For adequate potency, vaccines should contain 50 mean protective doses of antigen per dose, which corresponds to 0.3–7.8 μg of HA protein in inactivated vaccines, depending on immunogenicity and antigenic relatedness of individual seed strains.

Key words

Avian influenza Vaccine efficacy Laboratory assessment Licensure Vaccine 

Notes

Acknowledgments

The concepts for this chapter have been modified and updated from previous publications [29, 35].

References

  1. 1.
    Brown DW, Kawaoka Y, Webster RG, Robinson HL (1992) Assessment of retrovirus-expressed nucleoprotein as a vaccine against lethal influenza virus infections of chickens. Avian Dis 36:515–520CrossRefGoogle Scholar
  2. 2.
    Webster RG, Kawaoka Y, Taylor J, Weinberg R, Paoletti E (1991) Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine 9:303–308CrossRefGoogle Scholar
  3. 3.
    Swayne DE, Kapczynski DR (2008) Vaccines, vaccination and immunology for avian influenza viruses in poultry. In: Swayne DE (ed) Avian Influenza. Blackwell Publishing, Ames, Iowa, pp 407–451CrossRefGoogle Scholar
  4. 4.
    Swayne DE, Miller P (2009) Report of the subcommittee on avian influenza and Newcastle disease. Proc Annu Meet U S Anim Health Assoc 113:573–574Google Scholar
  5. 5.
    Swayne DE (2001) Avian influenza vaccine use during 2001. Proc Annu Meet U S Anim Health Assoc 104:469–471Google Scholar
  6. 6.
    Ellis TM, Leung CW, Chow MK, Bissett LA, Wong W, Guan Y, Peiris JSM (2004) Vaccination of chickens against H5N1 avian influenza in the face of an outbreak interrupts virus transmission. Avian Pathol 33:405–412CrossRefGoogle Scholar
  7. 7.
    Swayne DE, Pavade G, Hamilton K, Vallat B, Miyagishima K (2011) Assessment of national strategies for control of high pathogenicity avian influenza and low pathogenicity notifiable avian influenza in poultry, with emphasis on vaccines and vaccination. Rev Sci Tech 30:839–870CrossRefGoogle Scholar
  8. 8.
    Swayne DE, Sims L (2020) Avian influenza. In: Werner B (ed) Veterinary vaccines for livestock. Food and Agriculture Organization, Rome, in pressGoogle Scholar
  9. 9.
    OIE (2015) 2.3.4. Avian influenza. Manual of diagnostic tests and vaccines for terrestrial animals 2014. Accessed 16 May 2016Google Scholar
  10. 10.
    Rauw F, Palya V, Van BS, Welby S, Tatar-Kis T, Gardin Y, Dorsey KM, Aly MM, Hassan MK, Soliman MA, Lambrecht B, van den Berg T (2011) Further evidence of antigenic drift and protective efficacy afforded by a recombinant HVT-H5 vaccine against challenge with two antigenically divergent Egyptian clade 2.2.1 HPAI H5N1 strains. Vaccine 29:2590–2600CrossRefGoogle Scholar
  11. 11.
    Bertran K, Balzli C, Lee DH, Suarez DL, Kapczynski DR, Swayne DE (2017) Protection of white Leghorn chickens by U.S. emergency H5 vaccination against clade 2.3.4.4 H5N2 high pathogenicity avian influenza virus. Vaccine 35:6336–6344CrossRefGoogle Scholar
  12. 12.
    Oliveira CM, Vaughn E, Capua I, Cattoli G, Terregino C, Harder T, Grund C, Vega C, Robles F, Franco J, Darji A, Arafa AS, Mundt E (2017) A genetically engineered H5 protein expressed in insect cells confers protection against different clades of H5N1 highly pathogenic avian influenza viruses in chickens. Avian Pathol 46:224–233CrossRefGoogle Scholar
  13. 13.
    Anonymous (2017) DNA influenza vaccine licensed for chickens. Zootechnica, FlorenceGoogle Scholar
  14. 14.
    Liu J, Chen P, Jiang Y, Wu L, Zeng X, Tian G, Ge J, Kawaoka Y, Bu Z, Chen H (2011) A duck enteritis virus-vectored bivalent live vaccine provides fast and complete protection against H5N1 avian influenza virus infection in ducks. J Virol 85:10989–10998CrossRefGoogle Scholar
  15. 15.
    Chen H (2009) Avian influenza vaccination: the experience in China. Rev Sci Tech 28:267–274CrossRefGoogle Scholar
  16. 16.
    USDA (2018) Veterinary services memorandum no. 800.213. Licensing guidelines for production platform technology-based, non-replicating, nonviable vaccines. https://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_213.pdf. Accessed 25 Jan 2019
  17. 17.
    USDA (2007) Veterinary services memorandum no. 800.111. Viral strain changes in equine influenza and swine influenza vaccines (killed virus). https://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_111.pdf. Accessed 24 Jan 2019
  18. 18.
    Swayne DE, Kapczynski DR (2017) Vaccines and vaccination for avian influenza in poultry. In: Swayne DE (ed) Animal influenza. Wiley-Blackwell, Ames, Iowa, pp 378–434Google Scholar
  19. 19.
    USDA (2011) Standard operating policy/procedure. Master seed testing in the virology section. http://www.aphis.usda.gov/animal_health/vet_biologics/publications/VIRSOP2007.pdf. Accessed 21 Sep 2013
  20. 20.
    CDC NIH (2009) Biosafety in Microbiological and Biomedical Laboratories. https://www.cdc.gov/labs/pdf/CDC-BiosafetyMicrobiologicalBiomedicalLaboratories-2009-P.PDF. Accessed 9 Jan 2019
  21. 21.
    USDA (2002) ARS facilities design standards. Manual 242.1M-ARS. http://www.afm.ars.usda.gov/ppweb/242-01m.htm#H318. Accessed 21 Sep 2013
  22. 22.
    USDA (2003) Veterinary services memorandum no. 800.205. General licensing considerations: biotechnology-derived veterinary biologics categories I, II, and III. https://www.aphis.usda.gov/animal_health/vet_biologics/publications/memo_800_205.pdf. Accessed 25 Jan 2019
  23. 23.
    Pantin-Jackwood MJ, Costa-Hurtado M, Miller PJ, Afonso CL, Spackman E, Kapczynski DR, Shepherd E, Smith D, Swayne DE (2015) Experimental co-infections of domestic ducks with a virulent Newcastle disease virus and low or highly pathogenic avian influenza viruses. Vet Microbiol 177:7–17CrossRefGoogle Scholar
  24. 24.
    Haghighat-Jahromi M, Asasi K, Nili H, Dadras H, Shooshtari AH (2008) Coinfection of avian influenza virus (H9N2 subtype) with infectious bronchitis live vaccine. Arch Virol 153:651–655CrossRefGoogle Scholar
  25. 25.
    Nili H, Asasi K (2002) Natural cases and an experimental study of H9N2 avian influenza in commercial broiler chickens of Iran. Avian Pathol 31:247–252CrossRefGoogle Scholar
  26. 26.
    Swayne DE, Eggert D, Beck JR (2012) Reduction of high pathogenicity avian influenza virus in eggs from chickens once or twice vaccinated with an oil-emulsified inactivated H5 avian influenza vaccine. Vaccine 30:4964–4970CrossRefGoogle Scholar
  27. 27.
    Swayne DE, Beck JR, Mickle TR (1997) Efficacy of recombinant fowl pox vaccine in protecting chickens against highly pathogenic Mexican-origin H5N2 avian influenza virus. Avian Dis 41:910–922CrossRefGoogle Scholar
  28. 28.
    Tsukamoto K, Imada T, Tanimura N, Okamatsu M, Mase M, Mizuhara T, Swayne D, Yamaguchi S (2007) Impact of different husbandry conditions on contact and airborne transmission of H5N1 highly pathogenic avian influenza virus to chickens. Avian Dis 51:129–132CrossRefGoogle Scholar
  29. 29.
    Swayne DE (2008) Avian influenza vaccines and therapies for poultry. Comp Immunol Microbiol Infect Dis 32:351–363CrossRefGoogle Scholar
  30. 30.
    Swayne DE (2012) The role of vaccines and vaccination in high pathogenicity avian influenza control and eradication. Expert Rev Vaccines 11:877–880CrossRefGoogle Scholar
  31. 31.
    Swayne DE, Beck JR, Garcia M, Stone HD (1999) Influence of virus strain and antigen mass on efficacy of H5 avian influenza inactivated vaccines. Avian Pathol 28:245–255CrossRefGoogle Scholar
  32. 32.
    Swayne DE, Lee CW, Spackman E (2006) Inactivated north American and European H5N2 avian influenza virus vaccines protect chickens from Asian H5N1 high pathogenicity avian influenza virus. Avian Pathol 35:141–146CrossRefGoogle Scholar
  33. 33.
    Kumar M, Chu HJ, Rodenberg J, Krauss S, Webster RG (2007) Association of serologic and protective responses of avian infuenza vaccines in chickens. Avian Dis 51:481–483CrossRefGoogle Scholar
  34. 34.
    Thornton DH (1988) Quality control of vaccines. In: Alexander DJ (ed) Developments in veterinary virology: Newcastle disease. Kluwer Academic Publishers, Dordrecht, The Netherlands, pp 347–365Google Scholar
  35. 35.
    Swayne DE (2014) Laboratory methods for assessing and licensing influenza vaccines for poultry. In: Spackman E (ed) Animal influenza virus (2nd edition), methods Mol. Biol, vol 1161. Humana Press, New York, pp 185–198CrossRefGoogle Scholar

Copyright information

© This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply. 2020

Authors and Affiliations

  1. 1.Exotic and Emerging Avian Viral Diseases Research UnitUS National Poultry Research Center, Agricultural Research Service, US Department of AgricultureAthensUSA

Personalised recommendations